Published in N Engl J Med on November 24, 2005
American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken) (2012) 6.51
Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol (2009) 5.02
Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis (2012) 2.21
Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. Ann Rheum Dis (2010) 2.09
Trends in the incidence, demographics, and outcomes of end-stage renal disease due to lupus nephritis in the US from 1995 to 2006. Arthritis Rheum (2011) 1.68
Predicting outcomes of lupus nephritis with tubulointerstitial inflammation and scarring. Arthritis Care Res (Hoboken) (2011) 1.54
The frequency and outcome of lupus nephritis: results from an international inception cohort study. Rheumatology (Oxford) (2015) 1.54
Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study. Rheumatology (Oxford) (2009) 1.48
Value of a complete or partial remission in severe lupus nephritis. Clin J Am Soc Nephrol (2007) 1.39
Consensus treatment plans for induction therapy of newly diagnosed proliferative lupus nephritis in juvenile systemic lupus erythematosus. Arthritis Care Res (Hoboken) (2012) 1.33
Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial. Arthritis Res Ther (2012) 1.31
Renal involvement in autoimmune connective tissue diseases. BMC Med (2013) 1.21
Treatment of lupus nephritis with abatacept: the Abatacept and Cyclophosphamide Combination Efficacy and Safety Study. Arthritis Rheumatol (2014) 1.18
Why can't we find a new treatment for SLE? J Autoimmun (2009) 1.15
Systematic review and meta-analysis of randomised trials and cohort studies of mycophenolate mofetil in lupus nephritis. Arthritis Res Ther (2006) 1.15
Rituximab therapy for juvenile-onset systemic lupus erythematosus. Pediatr Nephrol (2007) 1.14
Long-term follow-up of the MAINTAIN Nephritis Trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis. Ann Rheum Dis (2015) 1.14
The spectrum of renal thrombotic microangiopathy in lupus nephritis. Arthritis Res Ther (2013) 1.13
Current and novel therapeutics in the treatment of systemic lupus erythematosus. J Allergy Clin Immunol (2011) 1.13
Dissecting the immune cell mayhem that drives lupus pathogenesis. Sci Transl Med (2011) 1.11
Systemic lupus erythematosus in children and adolescents. Pediatr Clin North Am (2012) 1.11
Bench-to-bedside review: pulmonary-renal syndromes--an update for the intensivist. Crit Care (2007) 1.10
Update on differences between childhood-onset and adult-onset systemic lupus erythematosus. Arthritis Res Ther (2013) 1.07
B-cell depletion in the treatment of lupus nephritis. Nat Rev Nephrol (2012) 1.05
Membranous nephropathy in systemic lupus erythematosus: a therapeutic enigma. Nat Rev Nephrol (2009) 1.05
Neuropsychiatric systemic lupus erythematosus. Curr Neuropharmacol (2011) 1.04
Immunotherapy of systemic sclerosis. Immunotherapy (2010) 1.03
Antibody-Mediated Autoimmune Encephalopathies and Immunotherapies. Neurotherapeutics (2016) 1.02
Disease activity assessment in SLE: do we have the right instruments? Ann Rheum Dis (2007) 0.99
Systemic lupus erythematosus. BMJ (2006) 0.98
Induction of remission in active anti-neutrophil cytoplasmic antibody-associated vasculitis with mycophenolate mofetil in patients who cannot be treated with cyclophosphamide. Ann Rheum Dis (2006) 0.98
Mycophenolate mofetil for induction and maintenance of remission in microscopic polyangiitis with mild to moderate renal involvement--a prospective, open-label pilot trial. Clin J Am Soc Nephrol (2010) 0.98
Immune and inflammatory role in renal disease. Compr Physiol (2013) 0.97
Lupus nephritis: current update. Arthritis Res Ther (2011) 0.97
Role of early repeated renal biopsies in lupus nephritis. Lupus Sci Med (2014) 0.97
Nanogel-based delivery of mycophenolic acid ameliorates systemic lupus erythematosus in mice. J Clin Invest (2013) 0.96
Three decades of progress in treating childhood-onset lupus nephritis. Clin J Am Soc Nephrol (2011) 0.96
Mediators of inflammation and their effect on resident renal cells: implications in lupus nephritis. Clin Dev Immunol (2013) 0.95
Value of repeat biopsy in lupus nephritis flares. Lupus Sci Med (2014) 0.95
High-dose cyclophosphamide versus monthly intravenous cyclophosphamide for systemic lupus erythematosus: a prospective randomized trial. Arthritis Rheum (2010) 0.94
Update on mesenchymal stem cell-based therapy in lupus and scleroderma. Arthritis Res Ther (2015) 0.93
Diagnosis and treatment of lupus nephritis flares--an update. Nat Rev Nephrol (2012) 0.92
New and emerging treatment approaches to lupus. Biologics (2010) 0.92
Vimentin is a dominant target of in situ humoral immunity in human lupus tubulointerstitial nephritis. Arthritis Rheumatol (2014) 0.91
Mycophenolate sodium treatment in patients with primary Sjögren syndrome: a pilot trial. Arthritis Res Ther (2007) 0.90
Pharmacokinetics of mycophenolic acid in patients with lupus nephritis. Pharmacotherapy (2009) 0.89
Oral cyclophosphamide for lupus glomerulonephritis: an underused therapeutic option. Clin J Am Soc Nephrol (2009) 0.88
Management of Neuropsychiatric Systemic Lupus Erythematosus: Current Approaches and Future Perspectives. Drugs (2016) 0.88
Therapy of lupus nephritis: lessons learned from clinical research and daily care of patients. Arthritis Res Ther (2012) 0.87
Glomerular disease: Lupus nephritis treatment: are we beyond cyclophosphamide? Nat Rev Nephrol (2009) 0.87
Expression of endothelial protein C receptor in cortical peritubular capillaries associates with a poor clinical response in lupus nephritis. Rheumatology (Oxford) (2009) 0.87
The efficacy of low-dose mycophenolate mofetil for treatment of lupus nephritis in Taiwanese patients with systemic lupus erythematosus. Clin Rheumatol (2010) 0.87
[Systemic lupus erythematosus--activity and outcome]. Z Rheumatol (2006) 0.87
Developments in the clinical understanding of lupus. Arthritis Res Ther (2009) 0.86
Mycophenolate mofetil plus prednisone for inducing remission of Henoch-Schönlein purpura nephritis: a retrospective study. J Zhejiang Univ Sci B (2015) 0.85
Understanding lupus nephritis: diagnosis, management, and treatment options. Int J Womens Health (2012) 0.85
National trends in pediatric systemic lupus erythematosus hospitalization in the United States: 2000-2009. J Rheumatol (2014) 0.85
Influence of clinical and demographic variables on mycophenolic acid pharmacokinetics in antineutrophil cytoplasmic antibody-associated vasculitis. Ann Pharmacother (2009) 0.84
Mycophenolate mofetil for lupus nephritis. N Engl J Med (2005) 0.84
Can mycophenolate mofetil substitute cyclophosphamide treatment of pediatric lupus nephritis? Pediatr Nephrol (2007) 0.84
The effect of mycophenolate mofetil on disease development in the gld.apoE (-/-) mouse model of accelerated atherosclerosis and systemic lupus erythematosus. PLoS One (2013) 0.83
Glomerular disease: perspectives on maintenance therapy in lupus nephritis. Nat Rev Nephrol (2012) 0.83
Connective tissue diseases: Management of lupus nephritis-new guidelines revealed. Nat Rev Rheumatol (2012) 0.83
Mycophenolic acid counteracts B cell proliferation and plasmablast formation in patients with systemic lupus erythematosus. Arthritis Res Ther (2012) 0.82
The development of membranous lupus nephritis during treatment with mycophenolate mofetil for proliferative renal disease. NDT Plus (2010) 0.82
An update on the use of mycophenolate mofetil in lupus nephritis and other primary glomerular diseases. Nat Clin Pract Nephrol (2009) 0.82
ESRD from lupus nephritis in the United States, 1995-2010. Clin J Am Soc Nephrol (2014) 0.82
Slowing chronic kidney disease progression: results of prospective clinical trials in adults. Pediatr Nephrol (2008) 0.81
Is newer safer? Adverse events associated with first-line therapies for ANCA-associated vasculitis and lupus nephritis. Clin J Am Soc Nephrol (2014) 0.81
Mycophenolate mofetil (MMF) does not slow the progression of subclinical atherosclerosis in SLE over 2 years. Rheumatol Int (2011) 0.81
National Lupus Hospitalization Trends Reveal Rising Rates of Herpes Zoster and Declines in Pneumocystis Pneumonia. PLoS One (2016) 0.81
[Statement on the use of mycophenolate mofetil for systemic lupus erythematosus]. Z Rheumatol (2013) 0.80
Targeting dendritic cell function during systemic autoimmunity to restore tolerance. Int J Mol Sci (2014) 0.80
Changes in immune cell frequencies after cyclophosphamide or mycophenolate mofetil treatments in patients with systemic lupus erythematosus. Clin Rheumatol (2012) 0.80
Adverse event burden, resource use, and costs associated with immunosuppressant medications for the treatment of systemic lupus erythematosus: a systematic literature review. Int J Rheumatol (2013) 0.80
Treatment of intractable pulmonary hemorrhage in two patients with childhood systemic lupus erythematosus. Rheumatol Int (2009) 0.80
Lupus nephritis: Implications of the new ACR lupus nephritis guidelines. Nat Rev Nephrol (2012) 0.80
Systemic lupus erythematosus: from genes to organ damage. Methods Mol Biol (2010) 0.80
Clearing the complexity: immune complexes and their treatment in lupus nephritis. Int J Nephrol Renovasc Dis (2011) 0.79
The evolution of drug discovery in systemic lupus erythematosus. Nat Rev Rheumatol (2015) 0.79
Contribution of dendritic cells to the autoimmune pathology of systemic lupus erythematosus. Immunology (2015) 0.79
Mycophenolate mofetil in the treatment of lupus nephritis. Biologics (2008) 0.79
Treatment of proliferative lupus nephritis: a slowly changing landscape. Nat Rev Nephrol (2010) 0.79
Towards new avenues in the management of lupus glomerulonephritis. Nat Rev Rheumatol (2016) 0.79
Cryoglobulinemic vasculitis in systemic sclerosis successfully treated with mycophenolate mofetil. Rheumatol Int (2012) 0.79
The treatment of systemic lupus proliferative nephritis. Pediatr Nephrol (2012) 0.79
Biomarkers for Refractory Lupus Nephritis: A Microarray Study of Kidney Tissue. Int J Mol Sci (2015) 0.78
Mycophenolate mofetil as maintenance therapy for proliferative lupus nephritis: a long-term observational prospective study. Arthritis Res Ther (2010) 0.78
Impact of recurrent lupus nephritis on lupus kidney transplantation: a 20-year single center experience. Clin Rheumatol (2012) 0.78
Inosine monophosphate dehydrogenase activity in paediatrics: age-related regulation and response to mycophenolic acid. Eur J Clin Pharmacol (2012) 0.78
Efficacy of long-term maintenance therapy with mycophenolate mofetil in lupus nephritis. Springerplus (2014) 0.78
Population pharmacokinetics of mycophenolic acid and metabolites in patients with glomerulonephritis. Ther Drug Monit (2010) 0.78
Systemic lupus erythematosus clinical trials-an interim analysis. Nat Rev Rheumatol (2009) 0.78
Comparison and evaluation of lupus nephritis response criteria in lupus activity indices and clinical trials. Arthritis Res Ther (2015) 0.78
Variability of the impact of adverse events on physicians' decision making. BMC Med Inform Decis Mak (2014) 0.78
Nanosized contrast agents to noninvasively detect kidney inflammation by magnetic resonance imaging. Adv Chronic Kidney Dis (2013) 0.78
Clinicopathological insights into lupus glomerulonephritis in Japanese and Asians. Clin Exp Nephrol (2011) 0.78
Sterile empyematous pleural effusion in a patient with systemic lupus erythematosus: a diagnostic challenge. Lupus (2009) 0.78
Recent clinical trials in lupus nephritis. Rheum Dis Clin North Am (2014) 0.78
Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat Genet (2007) 12.62
Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci. Nat Genet (2008) 12.51
Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med (2006) 10.95
Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX. N Engl J Med (2008) 9.61
Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum (2003) 8.50
The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol (2004) 7.38
A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus. Nat Genet (2006) 6.98
Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum (2012) 6.85
American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken) (2012) 6.51
Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility. Nat Genet (2011) 5.56
Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med (2005) 5.50
Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol (2009) 5.02
New therapies for treatment of rheumatoid arthritis. Lancet (2007) 4.80
The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int (2004) 4.77
Three functional variants of IFN regulatory factor 5 (IRF5) define risk and protective haplotypes for human lupus. Proc Natl Acad Sci U S A (2007) 4.71
Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum (2010) 4.57
Genetic association of the R620W polymorphism of protein tyrosine phosphatase PTPN22 with human SLE. Am J Hum Genet (2004) 4.46
Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med (2011) 4.08
Headache in systemic lupus erythematosus: results from a prospective, international inception cohort study. Arthritis Rheum (2013) 4.02
A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum (2011) 3.81
A nonsynonymous functional variant in integrin-alpha(M) (encoded by ITGAM) is associated with systemic lupus erythematosus. Nat Genet (2008) 3.71
Predictors of Pregnancy Outcomes in Patients With Lupus: A Cohort Study. Ann Intern Med (2015) 3.63
Genome-wide association study of ankylosing spondylitis identifies non-MHC susceptibility loci. Nat Genet (2010) 3.58
A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum (2009) 3.34
Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. Arthritis Rheum (2007) 3.12
The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann Intern Med (2005) 2.92
Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum (2006) 2.90
Cigarette smoking and the risk of systemic lupus erythematosus: a meta-analysis. Arthritis Rheum (2004) 2.88
C3 glomerulopathy: consensus report. Kidney Int (2013) 2.85
Eculizumab for dense deposit disease and C3 glomerulonephritis. Clin J Am Soc Nephrol (2012) 2.83
Bone marrow edema is the most specific finding for rheumatoid arthritis (RA) on noncontrast magnetic resonance imaging of the hands and wrists: a comparison of patients with RA and healthy controls. J Rheumatol (2009) 2.80
Brief report: airways abnormalities and rheumatoid arthritis-related autoantibodies in subjects without arthritis: early injury or initiating site of autoimmunity? Arthritis Rheum (2011) 2.74
Allogenic mesenchymal stem cells transplantation in refractory systemic lupus erythematosus: a pilot clinical study. Ann Rheum Dis (2010) 2.64
Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum (2009) 2.58
Utility of cardiac monitoring in fetuses at risk for congenital heart block: the PR Interval and Dexamethasone Evaluation (PRIDE) prospective study. Circulation (2008) 2.54
Association of a functional variant downstream of TNFAIP3 with systemic lupus erythematosus. Nat Genet (2011) 2.54
Elevated serum levels of interferon-regulated chemokines are biomarkers for active human systemic lupus erythematosus. PLoS Med (2006) 2.53
Fibrillary and immunotactoid glomerulonephritis: Distinct entities with different clinical and pathologic features. Kidney Int (2003) 2.47
Proliferative glomerulonephritis with monoclonal IgG deposits. J Am Soc Nephrol (2009) 2.45
The impact of tumor necrosis factor α inhibitors on radiographic progression in ankylosing spondylitis. Arthritis Rheum (2013) 2.40
Proliferative glomerulonephritis with monoclonal IgG deposits: a distinct entity mimicking immune-complex glomerulonephritis. Kidney Int (2004) 2.39
ANCA-associated glomerulonephritis in the very elderly. Kidney Int (2010) 2.36
Identification of autoantibody clusters that best predict lupus disease activity using glomerular proteome arrays. J Clin Invest (2005) 2.36
Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum (2005) 2.32
Identification of IRAK1 as a risk gene with critical role in the pathogenesis of systemic lupus erythematosus. Proc Natl Acad Sci U S A (2009) 2.31
Hydroxychloroquine in lupus pregnancy. Arthritis Rheum (2006) 2.27
Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse. J Clin Invest (2003) 2.26
Vitamin D deficiency in systemic lupus erythematosus. Autoimmun Rev (2005) 2.25
Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials. Arthritis Rheum (2013) 2.25
A risk allele for focal segmental glomerulosclerosis in African Americans is located within a region containing APOL1 and MYH9. Kidney Int (2010) 2.22
Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: a validation study. Arthritis Rheum (2009) 2.20
Progress toward the cure of rheumatoid arthritis? The BeSt study. Arthritis Rheum (2005) 2.15
Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. Arthritis Res Ther (2008) 2.15
The concept of axial spondyloarthritis: joint statement of the spondyloarthritis research and treatment network and the Assessment of SpondyloArthritis international Society in response to the US Food and Drug Administration's comments and concerns. Arthritis Rheumatol (2014) 2.14
The HLA-DRB1 shared epitope is associated with susceptibility to rheumatoid arthritis in African Americans through European genetic admixture. Arthritis Rheum (2008) 2.13
A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum (2003) 2.11
Dense deposit disease: clinicopathologic study of 32 pediatric and adult patients. Clin J Am Soc Nephrol (2008) 2.08
Insulin resistance in rheumatoid arthritis: disease-related indicators and associations with the presence and progression of subclinical atherosclerosis. Arthritis Rheumatol (2015) 2.07
Sifalimumab, a human anti-interferon-α monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study. Arthritis Rheum (2013) 2.06
Activated memory B cell subsets correlate with disease activity in systemic lupus erythematosus: delineation by expression of CD27, IgD, and CD95. Arthritis Rheum (2008) 2.00
Umbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus. Arthritis Rheum (2010) 1.98
Common variants within MECP2 confer risk of systemic lupus erythematosus. PLoS One (2008) 1.98
Differential genetic associations for systemic lupus erythematosus based on anti-dsDNA autoantibody production. PLoS Genet (2011) 1.92
Secondary Sjogren's syndrome in systemic lupus erythematosus defines a distinct disease subset. J Rheumatol (2010) 1.89
Lack of a functional alternative complement pathway ameliorates ischemic acute renal failure in mice. J Immunol (2003) 1.89
Predictors of survival in systemic lupus erythematosus. Medicine (Baltimore) (2006) 1.87
Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. Am J Nephrol (2003) 1.85
Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis (2012) 1.85
Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial. Ann Intern Med (2002) 1.84
A meta-analysis identifies new loci associated with body mass index in individuals of African ancestry. Nat Genet (2013) 1.82
Treatment of corticosteroid-responsive autoimmune inner ear disease with methotrexate: a randomized controlled trial. JAMA (2003) 1.81
Selective dysregulation of the FcgammaIIB receptor on memory B cells in SLE. J Exp Med (2006) 1.81
NPHS2 mutations in late-onset focal segmental glomerulosclerosis: R229Q is a common disease-associated allele. J Clin Invest (2002) 1.81
Collapsing glomerulopathy. Semin Nephrol (2003) 1.80
Specificity of the STAT4 genetic association for severe disease manifestations of systemic lupus erythematosus. PLoS Genet (2008) 1.80
Mutational and Biological Analysis of alpha-actinin-4 in focal segmental glomerulosclerosis. J Am Soc Nephrol (2005) 1.80